Predicting mortality risk of severe fever with thrombocytopenia syndrome: A multi-center retrospective cohort study

预测伴血小板减少症的重症发热患者的死亡风险:一项多中心回顾性队列研究

阅读:3

Abstract

Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne disease with high mortality, and clinical practice lacks dynamic tools to assess its rapidly evolving course. This study aims to develop stage-specific machine learning models to predict mortality risk using longitudinal biomarker data. We conducted a retrospective analysis of 5359 laboratory-confirmed SFTS patients from two hospitals in the highly endemic region in China. Serial measurements of 46 clinical and laboratory variables were integrated into a three-stage prognostic model developed using extreme gradient boosting (XGBoost). Within each clinical stage, key predictors and their relative contribution (RC) of mortality risk were assessed. Model performance was assessed based on discrimination, calibration, and decision curve analysis (DCA) in internal and external test sets. XGBoost models were constructed across 10 temporal phases, later consolidated into three clinically distinct stages via hierarchical clustering: early (≤7 days), intermediate (days 8-9), and late (≥10 days). Key predictors included age (dominant in early phase; RC, 18.44%), lactate dehydrogenase (LDH; RC peaking at 60.10% in late phase), and monocyte percentage (RC range from 5.25% to 16.04%). Pathophysiological shifts across clinical stages were revealed: early viral cytopathy (dominated by age and MONO%), intermediate immunopathology (marked by LDH surge), and late hepatic failure (dominated by LDH, AST, and TBA). The model showed strong discrimination (Area under the receiver operating characteristic curve, AUCs: 0.84-0.98 internal; 0.91-0.98 external), calibration (Brier scores: 0.04-0.11), and clinical utility via DCA. This study introduces a dynamic staging system that leverages predictive models and real-time patient data to monitor mortality risk and personalize SFTS care, which enables timely interventions to reduce deaths.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。